Overview Fundamentals API Earnings EOD API Sample Code Pricing

Tscan Therapeutics Inc (TCRX NASDAQ) stock market data APIs

$5.88 -0.04(-0.7%) as of September 10, 2024
Price chart is built with Anychart

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Tscan Therapeutics Inc Financial Data Overview

5.92
5.88
-
6.04
5.76
2.36-9.69
295 M
48 697 K
12 200 K
-0.28
0.783
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'TCRX',
Type: 'Common Stock',
Name: 'Tscan Therapeutics Inc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00PH1N007',
ISIN: NULL,
CUSIP: NULL,
CIK: '1783328',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2021-07-16',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Tscan Therapeutics Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 12 200 K
  • EBITDA -106 656 000
  • Earnings Per Share -0.65
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get Tscan Therapeutics Inc Earnings via APIs

  • Latest Release 2024-08-12
  • EPS/Forecast -0.28

Get Tscan Therapeutics Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?
support@eodhistoricaldata.com